Our Global Medical Advisory Board has set standards for what they consider to be excellent medical centers for the diagnosis and treatment of GBS and CIDP, MMN and related neuropathies. Based on levels of expertise, available treatments, facilities, and research capabilities, these are the medical centers that we can unequivocally recommend as “Centers of Excellence”….
INCbase Update Chronic inflammatory demyelinating polyneuropathy (CIDP) is a rare disorder that affects different people in different ways. The symptoms, treatment response, and disease course may vary from person to person, or even in the same person at different stages of the disease. As previously reported in 2017, INCbase is a study that intends to…
Research grants are made possible through the benevolence of many sources, including the Helen S. Manheimer Research Fund, contributions from individuals who have been personally touched by GBS, CIDP, or variants, and by several commercial sources. Through the generosity of these contributors, to whom the Foundation is most grateful, we are able continue our Research…
How do you respond to change? If you are interested in embracing change and growth, then consider these strategies for helping you to build resilience.
Join us on May 28, 2020 for a panel discussion on Results from CME Program: Differentiating GBS & CIDP in a Hospital Setting.
Dr. Amy Baxter presents: Bee Needle Fear Friendly This program will present options to assess and reduce needle fear, pain, and vasovagal syncope with Ig therapy, including topical anesthetics, cognitive interventions, and Buzzy best practices. After this program, the participant will be able to: Describe how differences in pharmacology and physiology influence analgesic choices for Ig procedures Cite…
COVID-19 Ask the Experts with Dr. Ken Gorson, part of our educational series featuring medical experts from the Foundation’s Global Medical Advisory Board.
The National Organization of Rare Disorders (NORD) launched a COVID-19 Critical Relief Program to provide much-needed assistance to members of the rare community affected by the current pandemic. The program provides financial relief that may be utilized to support critical, non-medical needs. The COVID-19 Critical Needs Non-Medical Assistance Fund provides eligible individuals impacted by the…
Grifols Announces Formal Collaboration with US Government to Produce the First Treatment Specifically Targeting COVID-19
By Dr. David Saperstein Antibodies (also known as immunoglobulins) play an important role in health and illness. Many of you regularly receive intravenous immunoglobulin (IVIG) to treat your autoimmune disease. Flooding a person’s system with antibodies from normal, healthy individuals can reverse problems caused by abnormally overactive immune systems. However, providing antibodies that fight a specific infection can…
The Plasma Protein Therapeutics Association (PPTA) has provided a statement specific to plasma protein therapies in light of the COVID-19 pandemic. CLICK HERE to read the statement. The PPTA notes that their Pathogen Safety Steering Committee continues to monitor the situation and is currently working on a broader update for the community. We will share these…
The coronavirus COVID-19 situation is evolving rapidly. In the interest of concerns and questions that the Foundation is receiving regarding the spread of the coronavirus COVID-19, the GBS|CIDP Global Medical Advisory Boards offers the following statement: GBS, CIDP and variants will not put patients at any higher risk of contracting the COVID-19, but those who…
By Diana Castro, MD Despite recovery of muscle weakness in most children, many patients experience persistent fatigue, pain and anxiety/depression. These symptoms can be incapacitating and can affect academic and social development. The mechanism underlying post-GBS fatigue is unclear. Fatigue can be secondary to stress and psychological factors. Other possibilities are deconditioning due to the…
By: Chelsey Fix Medicare is confusing – that’s a fact! Add the confusing Medicare system on top of a complex treatment for a rare disease, and it’s easy to feel overwhelmed. The Foundation is here to help all of our patients navigate health insurance headaches! For now this article explains the current Medicare situation for…
In 2019, The GBS|CIDP Foundation International was honored with a membership to the National Health Council (NHC). The Foundation joins over 140 other organizations, including major pharmaceutical companies, well-known patient support foundations, and respected professional societies, in their Membership. The mission of the NHC is to provide a united voice for the 160 million people…
Pagination
Spotlight
